The Canadian government needs to abolish pharmaceutical price controls, increase competition amongst drug makers by allowing advertising, stop the gray market in prescription drugs from Canada to the United States, and take other steps to improve pharmaceutical regulation, according to John R. Graham, Director, Health and Pharmaceutical Policy Research at The Fraser Institute. Graham testified before the House of Commons Standing Committee on Health in Vancouver on September 29.